A Retrospective Database Analysis of Prescribing Patterns for Specific Angiotensin Receptor Blockers

Saira A. Jan, MS, PharmD; Jay V. Patel, PharmD; John Welz, MPH; Patricia Ishak, PharmD

In This Article


Data for this study were obtained from medical and pharmacy claims of Horizon Blue Cross Blue Shield of New Jersey, a not-for-profit insurer with approximately 2.7 million covered lives, of which 1.7 million receive a pharmacy benefit. Data were extracted from the pharmacy claims database between August 1, 2002, and February 28, 2003. Members were included in the study if they were at least 18 years of age, had a diagnosis of hypertension as evidenced by medical claims, and had at least 2 consecutive prescriptions for the same ARB during the data-capture period. A subgroup of patients who had both hypertension and diabetes was also identified, and the data were analyzed.

The analysis focused on prescribing patterns for all products in the ARB class, both single entities and combinations with hydrochlorothiazide. The main outcome measure was daily average consumption (DACON), which is calculated by dividing quantity dispensed by reported days' supply. A DACON value of greater than 1.0 indicates that at least some persons are taking a medication more than once daily.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.